Desogestrel
Modify Date: 2024-01-02 17:40:53
Desogestrel structure
|
Common Name | Desogestrel | ||
|---|---|---|---|---|
| CAS Number | 54024-22-5 | Molecular Weight | 310.473 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 428.3±45.0 °C at 760 mmHg | |
| Molecular Formula | C22H30O | Melting Point | 109-110ºC | |
| MSDS | Chinese USA | Flash Point | 187.9±21.7 °C | |
| Symbol |
GHS09 |
Signal Word | Warning | |
Use of DesogestrelDesogestrel(Org-2969) is a third-generation 19-nortestosterone derivative progestogen; is contained in many oral contraceptive preparations, both combined (COCs) to ethinyl-estradiol (EE) or alone in a progestin-only pill (POP). |
| Name | desogestrel |
|---|---|
| Synonym | More Synonyms |
| Description | Desogestrel(Org-2969) is a third-generation 19-nortestosterone derivative progestogen; is contained in many oral contraceptive preparations, both combined (COCs) to ethinyl-estradiol (EE) or alone in a progestin-only pill (POP). |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 428.3±45.0 °C at 760 mmHg |
| Melting Point | 109-110ºC |
| Molecular Formula | C22H30O |
| Molecular Weight | 310.473 |
| Flash Point | 187.9±21.7 °C |
| Exact Mass | 310.229675 |
| PSA | 20.23000 |
| LogP | 6.59 |
| Vapour Pressure | 0.0±2.3 mmHg at 25°C |
| Index of Refraction | 1.566 |
| Storage condition | -20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
CAS#:54024-21-4
CAS#:74-86-2![(8S,9S,10R,14S)-13-ethyl-17-hydroxy-11-methylidene-1,2,6,7,8,9,10,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Structure](https://image.chemsrc.com/caspic/229/220332-82-1.png)
CAS#:220332-82-1
CAS#:161640-05-7
CAS#:54048-10-1|
Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies.
Arch. Gynecol. Obstet. 287(3) , 447-53, (2013) To evaluate the changes in the volume of rectovaginal endometriotic nodules infiltrating the rectum during 12-month treatment with hormonal therapies.This prospective, non-randomized, self-controlled ... |
|
|
The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
J. Thromb. Haemost. 11(1) , 124-31, (2013) Oral contraception (OC) and postmenopausal hormone therapy (HT) can be used to alleviate menopausal symptoms. However, the risk of venous thrombosis (VT) associated with OC use in women over 50 years ... |
|
|
Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura.
Eur. J. Obstet. Gynecol. Reprod. Biol. 179 , 63-8, (2014) Evaluate patient satisfaction at 6-month treatment in women with symptomatic rectovaginal endometriosis and migraine without aura with (progestogen-only contraceptive pill, POP versus sequential combi... |
| (8S,9S,10R,13S,14S,17R)-13-éthyl-17-éthynyl-11-méthylidène-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tétradécahydro-1H-cyclopenta[a]phénanthrén-17-ol |
| Desogestrel |
| (8S,9S,10R,13S,14S,17R)-17-Ethinyl-13-ethyl-11-methyliden-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol |
| (17α)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol |
| DESOGESTRAL |
| 13-Ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-ol |
| 17a-Ethynyl-18-methyl-11-methyl-ene-D4-estren-17b-ol |
| (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol (non-preferred name) |
| 13-ethyl-11-methylene-18,19-dinor-17a-pregn-4-en-20-yn-17-ol |
| org2969 |
| (17a)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol |
| Marvelon 150/320 |
| Cerazette |
| (8S,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-11-methylene-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol |
| Dicromil |
| (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol |
| Cyclosa |